I like your analysis. Only thing is we don’t know how long 5th...

First 20 Last

Share
Profile

Follow
jetrodder

6,633 Posts.

54

09/09/21

17:00

Post #: 55952779
Share

Originally posted by Gorillas95: ↑

Good luck Jetrodder getting info on 5th dossier from company, they will hide behind the commercially secret vail.

Its an interesting nuance in the company's communication where previously they only announced when dossier accepted for review, which implies they FDA can bounce the dossier even before the starters gun goes off but in the Financial Report the table indicates another dossier in with the FDA.

I admire your continued passion re Jublia but IMO I don't hold the same hopes around the opportunity, I feel the reporting around mkt size is mis-leading when you look at disclosures in the brand's investor reporting. Look at Bausch's fiscal releases and search for Jublia, nowhere near the USD 200mil that we have heard at times from ACR. Also, 12+ company's filed on the same day as us, so unless there dossiers are very poor that should be the number of competitors we expect when market opens to generics, post litigation at a date to be advised.

Biggest typo in the presentation was "Objective to be cash flow positive by end of 2022", call me a dis-believer but our approved and to be approved drugs need to start bringing in + 12.0mil annually in next 15 mths for this "objective" to be met.

There is a chance that the 4th and 5th dossiers will not be approved by Dec 2022 and we have no visibility as to whether our Jublia generic will be even on the market.

Expand

I like your analysis. Only thing is we don’t know how long 5th dossier has been with the FDA. It may have started out as number 1.

ACR Price at posting: 13.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

NUZ

Neurizon inks $1.5M loan against R&D Tax Rebate

HAR

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

IXR

Ionic Rare Earths falls -7% as momentum slips on vague production update

First 20 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $7.366M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	883823	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	500697	1

View Market Depth

No.	Vol.	Price($)
5	883823	0.017
10	962673	0.016
6	1361882	0.015
2	140000	0.014
3	486850	0.013

Price($)	Vol.	No.
0.018	500697	1
0.020	56617	4
0.021	111922	1
0.022	168642	2
0.023	381179	1

Last trade - 16.21pm 30/07/2025 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

I like your analysis. Only thing is we don’t know how long 5th...

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Ionic Rare Earths falls -7% as momentum slips on vague production update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I like your analysis. Only thing is we don’t know how long 5th...

Top Stories

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Ionic Rare Earths falls -7% as momentum slips on vague production update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News